Daré Bioscience, Inc. (NASDAQ: DARE) shares began Tuesday in the red. The company, calling itself a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced the launch of a strategic collaboration with MyMenopauseRx, a specialized telehealth platform focused exclusively on menopause care.
Under the collaboration, MyMenopauseRx will be featured as a menopause-specific telehealth partner for DARE to PLAY™ Sildenafil Cream. Women seeking dedicated menopause care, alongside arousal support, can now access a menopause specialist through MyMenopauseRx, with options for lifestyle counseling, bioidentical hormonal treatment and more, available by insurance or cash pay. This option sits alongside DARE to
PLAY's existing telehealth questionnaire and the option to consult a woman's own provider, giving women more ways to find the pathway that fits their care needs.
The collaboration represents an important expansion of Daré’s commercial strategy as the company works to build a broader women’s health ecosystem that connects its innovative products with education, clinical expertise and access to care.
Among millions of women navigating perimenopause, many experience changes in sleep, mood, energy and cognition, in addition to shifts in arousal and sexual function. By offering MyMenopauseRx as an option to
women exploring DARE to PLAY, Daré is looking to more directly serve the women looking for that broader support.
DARE gave back six cents, or 4.6%, to $1.26.
